Introduction
The clinical diagnosis of endometriosis has remained a challenge for physicians and scientists since the disease was first defined by John Sampson (1927) . Despite the advances observed in this field during the past 10 years, especially in imaging technology (Abrão et al., 2007; Bazot et al., 2009; Gonçalves et al., 2009; Saba et al., 2011) , which have mainly improved the diagnosis of deep endometriosis lesions, we still lack a good biochemical marker capable of diagnosing all stages of the disease, especially the early stages. Women with subfertility and/or pelvic pain, and a normal clinical examination as well as normal imaging results, would be the best beneficiaries from a noninvasive or semiinvasive test (Fassbender et al., 2013) . A good biomarker may serve to identify risk patients for disease prevention, as a potential drug target or marker for a drug response, and finally, as a control after treatment, being capable of detecting recurrence and progression of the disease (Palmer and Barnhart, 2013) . Currently, the most used marker with this goal is the serum level of the antigen CA 125, which was first related to endometriosis reported by Niloff et al., (1984) . Since then, several studies have succeeded in showing variable sensibility and specificity rates, which are not good enough for precise diagnosis of all stages and clinical presentations of the disease (Abrão et al., 1997; Somigliana et al., 2004; Xavier et al., 2005; Maiorana et al., 2007; Socolov et al., 2011) .
Although different markers have been tested and shown to be altered in patients with endometriosis compared with controls, as a noninvasive test (peripheral blood (PB) samples) and/or semi-invasive/invasive tests (eutopic endometrium samples/PF aspiration), to date none has been validated for clinical use as a diagnostic test in patients with endometriosis (May et al., 2010; Fassbender et al., 2013) . Biomarkers were assessed alone (Khorram et al., 1993; Bourlev et al., 2006; Cho et al., 2007) or in combination with a panel of markers (Agic et al., 2008; Seeber et al., 2008; Mihalyi et al., 2010; Vodolazkaia et al., 2012) . Khorram et al. (1993) were the first to demonstrate the relation between high levels of chemokines and endometriosis. During the past 20 years, many researchers have evaluated different types of chemokines in patients with endometriosis and matching controls in order to establish a possible role of chemokines in the pathogenesis of the disease (Borrelli et al., 2013) . Although the exact role of chemokines in the pathogenesis of endometriosis remains unsolved, it is possible that they are related to the aggressiveness, invasiveness and progression of the disease (Li et al., 2012a,b) .
Chemokines
Chemokines represent a family of small cytokines or proteins released by cells, especially lymphocytes, and are capable of inducing chemotaxis (directed movement through the chemicals of the microenvironment) in nearby responsive cells, directing the cellular migration. Some chemokines control cells of the immune system directing lymphocytes to lymph nodes, and they are called homeostatic chemokines. Inflammatory chemokines are released from a great variety of cells in response to bacterial infections, virus and other pathogenic agents. Therefore, they act under both physiological conditions and pathological processes (Acker et al., 1996; Lira and Furtado, 2012) .
Chemokines interact with specific receptors as we have explained in detail in our previous publication (Borrelli et al., 2013) .
Several studies have already assessed single or combined chemokines in patients with and without endometriosis, as possible markers for the disease (Laudanski et al., 2006; Agic et al., 2008; Othman et al., 2008; Socolov et al., 2011; Drosdzol-Cop et al., 2012; Margari et al., 2013) .
Objectives
The aim of this systematic review is to assess and review all studies that measured chemokines in patients with endometriosis and matching controls, to try to answer whether they could or could not be used as a marker for the disease.
Methods
The goal of this review was to verify the possibility of using chemokines as biomarkers for endometriosis, as a noninvasive test using PB samples, or even as a semi-invasive test using endometrial samples (eutopic endometrium), as well as a more invasive test using PF, which is currently obtained during laparoscopy-a surgical procedure. The review was based on the PRISMA statement (Moher et al., 2009 ). The quality of the individual studies was judged using a modified version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria (Whiting et al., 2003; May et al., 2010) (Table I) .
Search strategy
We used the MEDLINE database to seek relevant studies and searched the literature published from December 1993 to August 2013. The words 'endometriosis' and 'chemokines' or 'endometriosis' and 'biomarkers panel' as well as 'endometriosis' and 'chemokines' and 'biological markers' were used as key words to recover all possible publications on this theme at PubMed database. The strategies for electronic search at the MeSH database were the following combined 
Results

Eligibility criteria
We included all studies that measured at least one chemokine in patients with endometriosis and matching controls in PB, PF and eutopic endometrial samples (EES), and we excluded the studies that measured expression of chemokines in ectopic tissue, as this requires the removal of a suspect lesion, which is already the most used diagnostic tool for endometriosis worldwide through histologic examination. Although it might be possible to obtain PF in the future by means of a less invasive (semi-invasive) test such as the transvaginal ultrasound-guided aspiration, depending on the identification and validation of a reliable test in the PF, such samples are currently mostly obtained during laparoscopic procedures. From 329 initial papers originated through the primary computerized search (238 + 22 + 69), 148 studies were excluded by filters (Reviews, animal studies, not English Language) and duplicates. The abstracts of the 181 remaining references were read and using the inclusion/exclusion criteria described above, 117 were excluded and 64 were selected to be read in full, as well as two additional papers selected from the reference lists. Of the remaining 66 articles, three were excluded because they did not meet the inclusion criteria and one because it contained duplicate data thus 62 papers were included in this systematic review. They all measured chemokines in patients with endometriosis and compared with matching controls (Fig. 1) .
Data items
We extracted the following data from the selected studies-names of the chemokines measured, the type of samples taken, the phase of the menstrual cycle when the chemokines were measured, number of patients, stage of endometriosis (ASRM) of the patients in the study group, which patients composed the control group and, finally, their results in order to establish or not significance to the findings. We also draw, where available, the processing methods and storage conditions from used samples. Chemokines as biomarkers for endometriosis A total of 27 different chemokines were assessed from the 62 studies reviewed. The most studied chemokines, including their receptors, were CXCL8-51.6% (32/62), CCL2-38.7% (24/62) and CCL5-19.3% (12/62), respectively, as shown in Table II . The samples most often used to assess chemokines in the included papers were PF in 56.4% (35/62) of the studies, PB in 35.5% (22/62) and tissue-EES in 20.9% (13/62) of the studies. The way data and samples are differently collected and stored in many institutions, as well as the clinical data from studied subjects and the ideal controls are still a problem in endometriosis research. In order to reach a consensus on that, the World Endometriosis Research Foundation (WERF) created the Endometriosis Phenome and Biobanking Harmonisation Project (EPHect), whose purpose is to facilitate and enable large-scale, cross-centre, longitudinal, biomarker and treatment target discovery research, developing a detailed clinical phenotyping (phenome) data to be collected from women with endometriosis and controls to allow collaborative sub-phenotype discovery and validation analyses, as well as Standard Operating Procedures for banking of biological samples from women with endometriosis and controls, with respect to collection, transport, processing and long-term storage. As this normative will be ready and published soon, in Supplementary Table SI we present the processing methods and storage conditions from samples-liquids and tissue-of the papers included in this systematic review, where they were available, to later compare them with the EPHect consensus. As we can see, the methods used to process and store the samples vary considerably among the studies reviewed. Table III shows the modified QUADAS criteria analysis, the chemokines that were assessed and the number of subjects and controls included in each study. None of the selected studies fulfilled all methodological criteria. The most common failures were the uncertainty about the interpretation of the biomarker result, if it was or not blindly interpreted, if the diagnosis of endometriosis was made without knowledge of the test results, the poor selection criteria to define patients and control subjects, in addition to lack of adjustment for menstrual cycle and stage of disease.
Finally, Table IV summarizes the main data extracted from each study reviewed, including the chemokine(s) measured, the type of the sample, phase of the cycle of the collection (when mentioned), characteristics of the subjects and controls recruited, and, most importantly, their results showing or not statistical significance to the findings.
CXCL8 (IL-8)
More than half of the studies reviewed had evaluated the a-chemokine CXCL8 (IL-8/Interleukin-8) as a marker for endometriosis, measuring it in the PF (50%), PB (40.6%) and tissue-EES (12.5%). When measured in the PF, CXCL8 was found to be significantly higher in the endometriosis patients compared with controls in almost all studies reviewed (Ryan et al., 1995; Arici et al., 1996; Rana et al., 1996; Gazvani et al., 1998; Iwabe et al., 1998; Barcz et al., 2002; Pizzo et al., 2002; Calhaz-Jorge et al., 2003; Skrzypczak et al., 2005; Bersinger et al., 2006; Kalu et al., 2007; Kuroda et al., 2010; Milewski et al., 2011; Barcz et al., 2012; Malhotra et al., 2012) . Only Kim et al. (2009) found no statistically significant difference (P . 0.05) between patients with the disease and controls. However, their study included a small number of subjects and the controls had either dermoid cysts or cervical cancer, which could have influenced the results. Interestingly, Gazvani et al. (1998) observed better results in patients with endometriosis Stage I (ASRM) compared with controls, than all endometriosis patients together (Stages I -IV) versus controls.
On the other hand, the studies that evaluated the serum levels of CXCL8 presented conflicting results. Carmona et al. (2012) and Ohata et al. (2008) obtained similar results, both reporting significantly higher serum levels of CXCL8 in patients with ovarian endometriomas versus controls (Ohata et al., (2008) used ovarian benign cysts as controls), but did not achieve the same results for Deep Infiltrating Endometriosis (DIE) patients. While another four studies Pizzo et al., 2002; Mihalyi et al., 2010; Vodolazkaia et al., 2012) found higher and significant PB levels of CXCL8 chemokine in patients with endometriosis (Stages I -IV) compared with controls, seven others found no statistically significant difference (P . 0.05) of this potential marker among endometriosis subjects and controls (Gazvani et al., 1998; Fasciani et al., 2001; Barcz et al., 2002; Daraï et al., 2003; Kalu et al., 2007 
Table II
List of all assessed chemokines divided into their families and the number (n) of the 62 studies that included them.
Chemokine families
Chemokine biomarkers
CXCL-9 (MIG) 1 1.6 CXCL-10 (IP-10) 3 4.8 CXCL-11 (IP-9) 1 1.6 CXCL-12 (SDF-1) 1 1.6
XCL1 (SCM-1a) 1 1.6
ENA-78, epithelial-derived neutrophil-activating peptide-78; GCP-2, granulocyte chemotactic protein-2; GRO-a, growth regulated oncogene a; HCC, hemofiltrate CC cytokines; IL-8, interleukin-8; IP-10, interferon gamma induced protein-10; MIG, monokine induced by interferon gamma; MIP, macrophage inflammatory protein; RANTES, relegated upon activation, normal T cell expressed and secreted; SCM, single C motif-1; SDF, stromal cell derivded factor; TARC, thymus and activation regulated cytokine. 
Continued
Chemokines as biomarkers for endometriosis measured CXCL8 in the PB, 6 (46.1%) demonstrated its potential as a marker for endometriosis with diagnostic value. Few studies measured the expression of CXCL8 chemokine or its receptors CXCR1 and CXCR2 in EESs of women with and without endometriosis. All studies (Ulukus et al., 2009; Li et al., 2012a Li et al., , 2012b Rocha et al., 2012) found higher expression of CXCL8 in endometrial cells among patients with endometriosis compared with controls. When the CXCL8 receptors CXCR1 or CXCR2 were measured in place of the ligand (CXCL8), Ulukus et al. (2005) found higher expression from both receptors among endometriosis patients, while Li et al. (2012a,b) observed that only the expression of the receptor CXCR1 was higher.
CCL2 (MCP-1)
The second most evaluated chemokine, as a potential marker for endometriosis was the monocyte chemotatic protein-1 or CCL2, a member of the b-chemokine family. It has been measured in the PF (45.8%), PB (41.6%) and tissue -EES (33.3%). While 54.5% of the authors found statistically significant higher concentration of CCL2 in the PF among endometriosis patients compared with controls (Akoum et al., 1996a (Akoum et al., , 2002 Arici et al., 1997; Pizzo et al., 2002; Kalu et al., 2007; Tao et al., 2011) , 36.3% found no statistically significant difference (P . 0.05) between endometriosis patients and controls (Laudanski et al., 2006; Kim et al., 2008; Na et al., 2011; Drosdzol-Cop et al., 2012) . Furthermore, one group of investigators found significant lower concentrations of CCL2 among endometriosis patients compared with controls (Margari et al., 2013) .
After assessing the studies that measured serum levels of CCL2, we found the results well divided, with 50% showing significantly higher CCL2 concentration in PB in patients with the disease compared with that of controls (Akoum et al., 1996b; Pizzo et al., 2002; Gmyrek et al., 2005; Agic et al., 2008; Othman et al., 2008) , and the other 50% showing no statistically significant difference (P . 0.05) between the groups with or without endometriosis (Kalu et al., 2007; Kim et al., 2008; Seeber et al., 2008; Drosdzol-Cop et al., 2012; Vodolazkaia et al., 2012) .
The majority of the studies that evaluated CCL2 in the tissue-EESfound significantly higher expression of CCL2 in the EESs of patients with endometriosis compared with controls (Akoum et al., 1995; Jolicoeur et al., 1998; Kharfi and Akoum, 2001; Ulukus et al., 2009; Li et al., 2012a) , while two studies found no statistically significant difference (P . 0.05) (Kyama et al., 2008; Luk et al., 2010) . Analyzing the results from Li et al. (2012a, b) , we observe that they identified significant higher expression of CCL2 in endometrial samples of endometriosis patients compared with controls, but found no statistically significant difference (P . 0.05) of CCR2 (CCL2 receptor) expression in the same group of patients.
CCL5 (RANTES)
The b-chemokine CCL5, also known as RANTES (regulated upon activation, normal T cell expressed and secreted), was the first chemokine evaluated in association with endometriosis back in 1993. In this literature review, we observed that this chemokine was the third most assessed during the past 20 years as a possible marker for endometriosis. Studies on the CCL5 chemokine, as we have seen for the first two chemokines, CXCL8 and CCL2, also measured CCL5 in the PF (58.3%), PB (33.3%) and tissue-EES (16.6%). Here, the analysis of the PF also shows controversial results, with three publications (42.8%) revealing statistically significantly higher concentrations of CCL5 among endometriosis 
CCL2 ( 
CXCL8 (IL-8) PF Not mentioned
CCL2 (MCP-1) PF Not mentioned
CXCL8 ( 
Higher (,0.005)
CXCL1 (GRO-a) PF Not mentioned
Higher PF/PB (CCL2 and CXCL8): (,0.001)
Higher (,0.01)
n ¼ 78 (pain, infertility and tubal ligation)
CXCL8 ( NS, not significant; PF, peritoneal fluid; PB, peripheral blood; S, stage; L, luteal; F, follicular; M, menstrual; EDT, endometriosis; NM, not mentioned; E/C, endometriosis/controls; ENA-78, epithelial-derived neutrophil-activating protein-78; GCP, granulocyte chemotactic protein; GRO-a, growth regulated oncogene a; LEC, liver expressed chemokine; IL-8, interleukin-8; IP-10, interferon gamma induced protein-10; IUD, intrauterine device; MCP-1, monocyte chemotactic protein-1; MIP, macrophage inflammatory protein-1; RANTES, regulated upon activation, normal T cell expressed and secreted.
patients versus controls (Khorram et al., 1993; Hornung et al., 2001; Bersinger et al., 2006) , while another four (57.2%) found no statistically significant difference (P . 0.05) between the group with the disease and controls (Laudanski et al., 2006; Kalu et al., 2007; Na et al., 2011; Margari et al., 2013) . In blood samples, Agic et al. (2007 Agic et al. ( , 2008 found significantly higher levels of CCR1 (CCL5 receptor) mRNA in patients with endometriosis compared with controls without the disease, while Vodolazkaia et al. (2012) found increased levels of CCL5 (the ligand) in endometriosis patients compared with controls, which means that 75% of the studies had positive results assessing CCL5 in the blood. Only one paper (25%) from Kalu et al. (2007) found no statistically significant difference (P . 0.05) in the blood titles of CCL5 between the groups of patients and controls.
Only two studies assessed CCL5 in tissue and they did not have the same findings: Fang et al. (2009) found significantly higher expression of CCL5 in EESs from endometriosis patients compared with controls, while Kyama et al. (2008) found no statistically significant difference (P . 0.05) between the groups.
Others
Here, we describe the main findings for the other chemokines, which were assessed only once or twice in the studies reviewed. Bellelis et al. (2013) assessed the following chemokines-CCL17, CCL21, CXCL9, CXCL10, CXCL11, CXCL12, CX 3 CL1 and XCL1 via endometrial biopsies. They found significantly increased levels of CCL17 among patients with bowel endometriosis compared with controls and to patients with retrocervical endometriosis; the other chemokines did not show statistically significant difference (P . 0.05) in EES in patients with endometriosis compared with controls. Chand et al. (2007) evaluated the b-chemokines CCL16 (HCC4) and CCL21 (6Ckine) in tissue samples (EES) and observed that their expression was significantly higher in endometriosis patients compared with controls. After assessing the a-chemokine CXCL10 (IP-10/interferon-g-induced protein-10) in the PF and PB, Galleri et al. (2009) found significantly lower concentrations of this chemokine among all stages endometriosis patients in the PB and also significantly lower concentrations among Stages III -IV in the PF, while Kim et al. (2009) found no statistically significant difference (P . 0.05) of CXCL10 levels in the PF of patients with the disease compared with controls. Hornung et al. (2000) studied the CCL11 chemokine (eotaxin) in the PF and found significantly higher concentrations among endometriosis patients with Stages III -IV, but no statistically significant difference (P . 0.05) for Stages I -II compared with controls. Laudanski et al. (2006) used a mini-array of nine different b-chemokines (CCL2, CCL3, CCL4, CCL5, CCL15, CCL17, CCL19, CCL20 and CCL22) and assessed their concentrations in the PF of women with and without endometriosis, finding significantly higher concentration of only the CCL19 (MIP-3b) among endometriosis patients, and this was not related to the stage of disease. Margari et al. (2013) evaluated another b-chemokine, the CCL7, in the PF and found no statistically significant difference (P . 0.05) between the group with the disease and controls. Two studies assessed the a-chemokine CXCL5 (ENA-78) and both found that its concentrations were significantly higher in the PF of women with endometriosis compared with controls (Mueller et al., 2003; Suzumori et al., 2004) . The CX 3 CL1 chemokine (Fractalkine) was assessed in the PF and in PB samples by Shimoya et al., (2005) , but no statistically significant difference (P . 0.05) was found between patients and controls in serum samples; however, in the PF, its levels were significantly lower in patients with endometriosis compared with controls, suggesting a lack of peritoneal immunological protection in patients with the disease. Two studies (Oral et al., 1996; Szamatowicz et al., 2002) assessed the chemokine growth-regulated-alpha (GRO-a)-CXCL1-in the PF of patients with endometriosis and controls: the former found significantly higher levels only among patients with endometriosis Stages III -IV compared with controls, while the latter found significantly higher levels of this chemokine in all endometriosis patients, regardless of the stage of disease. The last different type of chemokine assessed among the reviewed studies was the CXCL6 (GCP-2), by Suzumori et al. (2005) , and their results showed a higher concentration of this chemokine in the PF of women with endometriosis (any stage) compared with controls.
Discussion
It is definitely not an easy task to find a good marker capable of diagnosing endometriosis at all stages, although it is a very important issue in endometriosis research (May et al., 2010) . This might be more difficult to establish with chemokines due to their role in several unspecific inflammatory pathways and chronic diseases, which sometimes makes it hard to distinguish patients and controls when using them as biomarkers. Nevertheless, this review of the literature has shown a large number of studies that investigate many different subtypes of chemokines as possible biological markers for endometriosis. Despite the controversial results presented, there were a great number of significantly positive findings among the 62 studies included in this systematic review.
Considering all the chemokines assessed and all types of samples across the studies reviewed, ca. 55% of the tests showed significantly increased chemokines levels among endometriosis patients, and if we consider only the three most studied chemokines (CXCL8, CCL2 and CCL5), this percentage rises up to 63.5%. Furthermore, if we look at the results of some specific chemokines alone, CXCL8 (IL-8) showed significantly higher levels in 72.7% of the tests, considering all samples, or even 93.75%, when assessed in the PF and 75% in the tissue-endometrial samples. The blood evaluation of CXCL8 showed significantly higher levels in 46.1% of the tests, while 53.9% of them did not find any difference. Nevertheless, we highlight the findings from Mihalyi et al. (2010) and Vodolazkaia et al. (2012) , two well-designed studies with a great number of subjects that showed statistically higher levels of this chemokine in the PB, demonstrating its potential for diagnostic value. Generally, all the findings suggest that CXCL8 certainly has a stronger tendency to have diagnostic value in the PF and endometrial samples, regardless of the stage of disease, and it might also have this potential in the PB.
Although the results from the chemokine CCL2 are controversial in all three different types of samples, overall they show a tenuous tendency to have diagnostic value, as 54.5% of the authors found statistically significantly higher concentration of CCL2 in the PF among endometriosis patients versus controls, while 71.4% presented such results in the endometrial samples, although, in both cases, the results generally did not vary according to the stage of disease. The results were well divided only when assessed in the PB, with 50% showing significantly higher levels, while the other 50% did not find any difference.
We observed the same tenuous tendency for CCL5 (RANTES) to have diagnostic value as we did for CCL2. The best results were in the PB, where 75% of the studies found significantly higher levels of this chemokine among endometriosis patients compared with controls, regardless of the stage of disease.
Many other chemokines were assessed alone, only once or twice, and they also showed significantly higher levels among endometriosis patients versus controls, such as CCL11 (Hornung et al., 2000) , CCL16 (Chand et al., 2007) , CCL17 (Bellelis et al., 2013) , CCL19 (Laudanski et al., 2006) , CCL21 (Chand et al., 2007) , CXCL1 (Oral et al., 1996; Szamatowicz et al., 2002) , CXCL5 (Mueller et al., 2003; Suzumori et al., 2004) and CXCL6 (Suzumori et al., 2005) .
We consider three major issues to explain the current controversial results in the evaluation of chemokines as possible markers for endometriosis patients: (i) first, the studies design, including here the sample size, the patients and controls selection criteria, as well as the criteria to assess the markers (phase of the menstrual cycle, stage of disease), as we could assess using the modified QUADAS criteria; (ii) second, we believe that evaluating one chemokine alone may not be the best way to find a good biological marker for endometriosis, but rather the association between some of them, in a panel of markers, as proposed before with other kinds of potential biological markers in a multivariate analysis (Vodolazkaia et al., 2012) ; and (iii) third, the real value of inflammatory markers, as chemokines, in the distinction of patients with endometriosis from women without endometriosis but with other pelvic pathologies.
Therefore, future analyses should test the most relevant chemokines in a panel of biomarkers models, combined or not with other noninflammatory markers that have already been tested and shown to have good potential in previous studies, in order to reach better and concrete results. The three main chemokines assessed to date-CXCL8, CCL2 and CCL5-would certainly present better results in welldesigned, large-scale and multi-centre studies, as the new consensus from the project 'EPHect' will enable. Agic et al., (2008) have already done it using the combination of CCR1 (RANTES/CCL5-receptor) mRNA, MCP-1 (CCL2) and CA125 measurements in the PB as a diagnostic test for endometriosis. This combination showed good results, with 92.2% sensitivity, 81.6% specificity, negative predictive value of 83.3%, positive predictive value of 92.3% and, most importantly, a likelihood ratio of a positive test result of 5.017, and a likelihood ratio of a negative test result of 0.096 to predict the presence or absence of endometriosis. Vodolazkaia et al. (2012) also evaluated a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis, which included three chemokines (IL-8/CXCL8, MCP-1/CCL2 and RANTES/CCL5). Although they have found significantly positive results for IL-8 and RANTES, as we have presented in the results of this present review, they did not include any of them in the two models of four biomarkers (anexin V, VEGF, CA125 and glycodelin or anexin V, VEGF, CA125 and sICAM-I) suggested as a potential blood test with good performance for endometriosis, with high sensitivity and acceptable specificity in patients with subfertility and/or pain without imaging findings.
In the two publications discussed above, the association of markers improved the diagnostic performance better than any of the biomarkers assessed alone, and this is probably the best approach for future investigations, regardless of the type of markers involved in the study. With this systematic review, we can conclude that chemokines certainly play an important role in the pathogenesis of endometriosis. However, it remains unclear whether they can or cannot be used as markers to diagnose and predict the development of endometriosis. For the first time in the literature, all chemokines that were once tested for endometriosis were appraised in a systematic matter and we could increase our knowledge with relevant information. Based on that, future research in the field should be conducted in better-designed, large-scale and multi-centre studies, as we have mentioned before. In our opinion, chemokines have the potential to be used as a marker and, perhaps, as a diagnostic test for endometriosis. Nevertheless, further investigations should be considered in this matter following the reasoning of the combination of markers as an ideal test for endometriosis, especially if associated with other non-inflammatory markers. We may then reach the validation stage of a good test.
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